Eisai Co., Ltd.
4523.T
Unten findest du den Live-Kurs für Eisai Co., Ltd. (4523.T), einen 1-Jahres-Chart, 8 Indikatoren (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volumen) und einen Vergleichsmodus. Hinzufügen zum Portfolio, auf die Beobachtungsliste setzen oder einen Preisalarm einrichten — alles in einem.
- Prev close
- $24.77
- Volume
- $3.78K
- Market cap
- $6.96B
- Currency
- USD (native JPY)
Financials
- 52w high
- ¥5,349
- 52w low
- ¥3,719
- 52w change
- -6.05%
- Day high
- ¥3,856
- Day low
- ¥3,790
- P/E (TTM)
- 27.74
- Forward P/E
- 18.75
- PEG
- 26.43
- Price / Book
- 1.19
- Beta (5Y)
- -0.11
- Enterprise value
- 1.04T
- EV / Revenue
- 1.26
- EV / EBITDA
- 11.28
- EPS (TTM)
- ¥136.96
- Forward EPS
- ¥202.57
- Dividend yield
- 4.19%
- Dividend rate
- ¥160
- Payout ratio
- 116.98%
- Revenue (TTM)
- 825.38B
- EBITDA
- 92.42B
- Free cash flow
- -21.68B
- Total cash
- 245.42B
- Total debt
- 186.08B
- Debt / Equity
- 20.11
- Current ratio
- 2.24
- Quick ratio
- 1.39
- Profit margin
- 4.67%
- Gross margin
- 76.83%
- Return on assets
- 2.33%
- Return on equity
- 4.53%
- Shares outstanding
- 282.11M
- Float
- 281.16M
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in India. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Analyst & Risk
- Beta (vs S&P 500)
- -0.11
- very stable
- 52-week change
- -6.05%
- Debt / Equity
- 20.11
- very high leverage
- Current ratio
- 2.24
- Quick ratio
- 1.39
- ROE
- 4.53%
- ROA
- 2.33%
- PEG ratio
- 26.43
- richly valued
- EV / Revenue
- 1.26
- EV / EBITDA
- 11.28
- Revenue growth
- 9.10%
- EBITDA
- 92.42B
- Free cash flow
- -21.68B
- Total cash
- 245.42B
- Total debt
- 186.08B
- Insider holdings
- 6.00%
- Institutional
- 56.04%
Aktuelle Nachrichten
- Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH TrialMarketBeat5m ago
- Uber reveals an unexpected problem behind the AI boomTheStreet7m ago
- Dow Jones Futures: Techs Fall After Dow Hits High, AI Shrugs Off Broadcom, Ciena; Jobs Report LoomsInvestor's Business Daily7m ago
- NMAA board approves 'one free transfer' rule; schools get final sayAlbuquerque Journal, N.M.9m ago
- New Mexico's AG files suit against sports betting firm KalshiAlbuquerque Journal, N.M.11m ago
- Why Ollie's (OLLI) Shares Are Sliding TodayStockStory12m ago
- Microsoft Held Up as AI Chips Sold Off. Is It the Safer Megacap Bet Now?Motley Fool13m ago
- Mitsubishi Electric to Launch Data-provision Service to Accelerate Adoption of Latest Power SemiconductorsBusiness Wire14m ago
Live-Diskussion
Anmelden to join the discussion.
- Noch keine Kommentare. Sei der Erste.